DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Aarti Pharmalabs Limited (AARTIPHARM) share price today?

Aarti Pharmalabs Limited (AARTIPHARM) is trading at ₹876.95 on the NSE, up 1.52% on the day. Source: DocStoX.

What is the PE ratio of Aarti Pharmalabs Limited?

Aarti Pharmalabs Limited has a price-to-earnings (PE) ratio of 45.5 in the Healthcare sector.

What is the market capitalisation of Aarti Pharmalabs Limited?

Aarti Pharmalabs Limited has a market capitalisation of approximately ₹7,936 crore.

Is Aarti Pharmalabs Limited a profitable company?

Aarti Pharmalabs Limited generates a return on equity of 8.1% with a net profit margin of 9.6%. That is a modest return on shareholder capital.

What is the 52-week high and low of AARTIPHARM?

Aarti Pharmalabs Limited (AARTIPHARM) has traded between ₹585 and ₹1,002.4 over the past 52 weeks, against a current price of ₹876.95.

Does Aarti Pharmalabs Limited pay a dividend?

Yes. Aarti Pharmalabs Limited currently offers a dividend yield of 0.42%. Dividend payments depend on the board's declaration each year.

Aarti Pharmalabs Limited

₹876.95▲ +13.15 (+1.52%)

AARTIPHARM·NSE·Healthcare

Market Cap

7935.84 Cr

PE Ratio

45.51

Volume

3,07,606

Day High - Low

890.65 - 864.85

52W High-Low

1002.40 - 585.00

₹876.95▲ +13.15 (+1.52%)

Market Cap7935.84 Cr

PE Ratio45.51

Volume3,07,606

Day High - Low890.65 - 864.85

52W High-Low1002.40 - 585.00

Aarti Pharmalabs Limited (AARTIPHARM): company summary

The company's business has declined over the past year, with annual revenue falling 14.0% and annual net profit dropping 35.8%.

Aarti Pharmalabs Limited (AARTIPHARM) is a small-cap Healthcare company valued at ₹7,936 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Aarti Pharmalabs Limited last traded at ₹876.95, modestly up 1.52% on the day.
Recent developments: 2026-08-10: Aarti Pharmalabs shares hit the 20% upper circuit after reporting a 65.4% year-on-year increase in Q1 FY27 net profit to ₹76.14 crore, with revenue rising 38.7% to ₹535.79 crore.
Financial performance: The company's business has declined over the past year, with annual revenue falling 14.0% and annual net profit dropping 35.8%. However, the latest quarter saw revenue rise 38.8% compared to the same quarter a year earlier, and net profit surged 52.3%.
Valuation multiples: The stock trades at 45.5 times earnings, a premium to the Healthcare median of 32.0, 3.52 times book value. It yields 0.4%.
Things to watch: The company's net profit margin has narrowed by 3.3 percentage points to 9.6%, and annual net profit has declined 35.8% over the past year. Promoter holding has decreased by 0.22 percentage points in the latest quarter.
Where it stands: Aarti Pharmalabs reported a strong performance in the latest quarter, with net profit rising 52.3% and revenue up 38.8% compared to the same quarter a year earlier. The company's net profit margin remains at 9.6%, and promoter holding has decreased slightly. The stock is 3.4% below its 52-week high.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

3.7/10

Poor

Fair Value

ROE

8.13%

Average

P/E

45.51x

Expensive

Debt / Equity

0.36

Moderate

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹864.85

₹890.65

52W₹585.00

₹1002

DocStoX take

Supported by risk (7.6) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 7.6, but that is offset by valuation at 0.0 and growth at 1.1. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

3.7

/10

Poor

Quality

Modest

ROE 8.1%

Valuation

Expensive

P/E 45.5×

Growth

Flat

Revenue -2.2% 3Y CAGR

Risk

Low risk

D/E 0.36

Momentum

Strong

70% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹877

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹7,936 Cr

52W High / Low

₹1002 / ₹585

Dividend Yield

0.42%

Promoter Holding

42.86%

EPS (TTM)

₹19.27

Book Value

₹234.35

Key highlights

Profitable in all of the last 5 years
Profit shrinking 3% a year
Revenue shrinking 2% a year

1 Positive4 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Aarti Pharmalabs Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Aarti Pharmalabs Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Aarti Pharmalabs Limited with peers

Aarti Pharmalabs Limited vs Sun Pharmaceutical Industries Limited Aarti Pharmalabs Limited vs Divi's Laboratories Limited Aarti Pharmalabs Limited vs Torrent Pharmaceuticals Limited Aarti Pharmalabs Limited vs Apollo Hospitals Enterprise Limited Aarti Pharmalabs Limited vs Zydus Lifesciences Limited Aarti Pharmalabs Limited vs Laurus Labs Limited

Related tools & concepts

Value Aarti Pharmalabs Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

AARTIPHARM newsLatest coverage & filings Open screenerFilter the whole market